myTomorrows is working with CUN on AI-supported matching of affected person surveys
Netherlands-based myTomorrows has partnered with Clínica Universidad de Navarra (CUN) to implement AI matching of medical trials, combine it into CUN’s digital well being file (EHR) and function inside the managed medical setting.
This collaboration marks myTomorrows’ first complete website partnership in Spain.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra data
Based on myTomorrows, the partnership brings forth an AI-driven eligibility help system aimed toward enhancing that course of inside present medical workflows.
The system makes use of giant language fashions to judge each unstructured medical documentation in numerous languages and structured medical variables corresponding to staging, analysis, earlier therapies and molecular profile.
Affected person knowledge is then systematically in comparison with protocol-defined eligibility standards and real-time cohort standing in CUN’s lively research.
Clinicians can immediately entry a structured record of eligible research in a affected person’s file throughout routine assessments. This integration helps constant screening throughout all tumor boards, pre-consult checks and outpatient workflows, minimizing handbook cross-referencing and decreasing the chance of lacking particular cohorts.
CUN medical doctors first assessed AI matching capabilities in a safe net setting that complies with the Common Information Safety Regulation (GDPR) utilizing actual medical situations.
Following analysis, the know-how was built-in into CUN’s EHR and trial administration techniques, enabling direct operation inside the hospital infrastructure.
The partnership additionally goals to strengthen referral coordination between CUN and exterior establishments.
Utilizing myTomorrows’ know-how, a CUN-branded web site will present referring physicians with real-time perception into the previous’s ongoing research and the standing of cohorts.
On this safe, GDPR-compliant setting, physicians may have the power to pre-screen sufferers utilizing AI towards CUN’s portfolio and submit referrals primarily based on the newest eligibility standards and cohort availability.
By enabling a pre-submission evaluation of eligibility, this mannequin improves readability of communication, minimizes administrative exchanges, and ensures referrals align with present necessities of CUN’s research.
CUN will present ongoing suggestions to refine the mannequin as myTomorrows’ first companion website in Spain.
myTomorrows CEO Michel van Harten mentioned: “This partnership displays the kind of collaboration we wish to scale globally. CUN’s established status in medical analysis and know-how adoption, mixed with its experience as a reference middle, makes it a trusted companion as we proceed to construct extra systematic and scalable options for medical trial operations.
“We sit up for working intently with CUN, constructing on real-world medical expertise to additional strengthen these fashions, and increasing with companions who share CUN’s dedication to extra effectively connecting sufferers to revolutionary, evolving therapies.”
In August 2024, MyTomorrows partnered with multi-stakeholder strain group Pancreatic Most cancers Europe in an effort to extend entry to new therapies throughout the continent via the corporate’s medical trial database.
